

Onyx Docket No.: ONYX1047-DIV
USSN: 10/669,768
Patent

Complete Listing Of The Claims

1-10. (Canceled)

**RECEIVED
CENTRAL FAX CENTER**

JUL 15 2008

11. (Previously Presented) A method of treating a cancer, characterized by neoplastic cells that substantially lack p53 function, in a patient in need of the treatment, comprising administering chemotherapy to said patient,

administering to said patient a dose of a recombinant adenovirus, said recombinant adenovirus comprising a mutation in the E1B-55K gene, said gene encoding a mutated E1B-55K protein comprising a single amino acid substitution mutation, said single amino acid substitution mutation reducing the ability of said mutated E1B-55K protein to bind to the tumor suppressor p53 when compared to the ability of wild-type E1B-55K protein to bind to the tumor suppressor p53 and said recombinant adenovirus has the further property of retaining late viral function, and

allowing sufficient time for said recombinant adenovirus to infect neoplastic cells of said cancer.

12. (Previously Presented) The method of claim 11, further comprising concomitantly administering said recombinant adenovirus with the chemotherapy.

13. (Previously Presented) The method of claim 11, wherein said adenovirus is Onyx 051 or Onyx 053.

14-23. (Canceled)

24. (Previously Presented) The method of treating cancer of claim 11, wherein said treatment is repeated.

25. (Previously Presented) The method of treating cancer of claim 13, wherein said recombinant adenovirus is Onyx 051.

Onyx Docket No.: ONYX1047-DIV
USSN: 10/669,768
Patent

26. (Previously Presented) The method of treating cancer of claim 13, wherein said recombinant adenovirus is Onyx 053.
27. (Previously Presented) The method of treating cancer of claim 11, wherein said mutated E1B-55K protein comprises a single amino acid substitution mutation in amino acid 240 or 260.
28. (Previously Presented) The method of treating cancer of claim 11, wherein replication of said recombinant adenovirus is cold insensitive.
- 29-32. (Canceled)
33. (Previously Presented) A method of treating a cancer, characterized by a tumor comprising neoplastic cells that substantially lack p53 function, in a patient in need of the treatment, comprising
 - administering chemotherapy to said patient,
 - administering by direct injection into the tumor a dose of a recombinant adenovirus, said recombinant adenovirus comprising a mutation in the E1B-55K gene, said gene encoding a mutated E1B-55K protein comprising a single amino acid substitution mutation, said single amino acid substitution mutation reducing the ability of said mutated E1B-55K protein to bind to the tumor suppressor p53 when compared to the ability of wild-type E1B-55K protein to bind to the tumor suppressor p53 and said recombinant adenovirus has the further property of retaining late viral function, and
 - allowing sufficient time for said recombinant adenovirus to infect neoplastic cells of said cancer.
34. (Canceled)
35. (Previously Presented) The method of claim 33, wherein said adenovirus is Onyx 051 or Onyx 053.

Onyx Docket No.: ONYX1047-DIV
USSN: 10/669,768
Patent

36. (Previously Presented) The method of treating cancer of claim 35, wherein said recombinant adenovirus is Onyx 051.

37. (Previously Presented) The method of treating cancer of claim 35, wherein said recombinant adenovirus is Onyx 053.

38. (Previously Presented) The method of treating cancer of claim 33, wherein said mutated E1B-55K protein comprises a single amino acid substitution mutation in amino acid 240 or 260.

39. (Previously Presented) The method of treating cancer of claim 33, wherein replication of said recombinant adenovirus is cold insensitive.

40. (Previously Presented) The method of treating cancer of claim 33, wherein said treatment is repeated.

41-47. (Canceled)